Vanquishing Apathy Through E-inclusion Using Realistic Virtual Environment Project (VERVE)

August 31, 2015 updated by: Centre Hospitalier Universitaire de Nice

VERVE* PROJECT: Study of the Acceptability of a Virtual Reality System on the Cognitive Stimulation of Patients With Alzheimer's Disease or Related Conditions. (*Vanquishing Apathy Through E-inclusion Using Realistic Virtual Environment)

Virtual environments and information communication technologies (ICT) offer large perspectives in the field of assistive care and rehabilitation.

As potentially endless, the scenarios and environment used using 3D can provide immersive social and interactive context for enjoyable and therapeutic exercises in the aging population. In addition it is also possible to use this type of serious game and scenario in very easy to use devices such as lap top or tablet.

Social exclusion has many causes, Apathy as one of the most common behavioural disturbances found in old adults populations alters significantly social and emotional interaction.

Even though, progress in VR has been made over the past year, the presence of such technology in daily living space is still at the embryonic stage.

The European e-Inclusion policy stresses the importance of ICT in improving the quality of life in potentially disadvantaged groups, including older people and persons.

The VERVE project is developing ICT tools to support the treatment of people who are at risk of social exclusion due to apathy associated with a disability.

As people aged and autonomy worsen fear for safety and comfortable means to maintain social and Health Related Quality of Life (HRQL) status are public health issues.

Moreover, even though older adults would like to perform some activities such as walking in the streets some are reluctant to go out of their homes as the external environment is perceived as potentially unsafe.

Apathy, the most common behavioural symptoms in aging population is characterized by symptoms of reduced initiation and responsiveness to environmental interactions. The syndrome of Apathy takes form of diminished goal-directed behaviour, characterised by emotional blunting, loss of initiative and loss of interest. Apathy along with the nosological characteristics of dementia induces impairment in autonomy level and therefore dependence as cognitive impairments worsened.

The importance of stimulation could be related to the concept of engagement defined as the act of being occupied or involved with an external stimulus. Engaging older person with or without Alzheimer's disease and related disorders in appropriate activities has been shown to yield beneficial HRQL effects such increasing positive emotion, improving cognition, functional autonomy and quality of life.

Accordingly, enriched environments with high definition virtual representation of cities and activities of interest have the potentials not only to encourage patients to get active in a safe and interactive environment but also to create access to enjoyable and stimulating settings for the more severe patients.

The VR setting from VERVE proposed personalised and populated environments available on two different, but interlinked hardware platforms: 1/: standard gaming set-up in the home, nursing home or day hospital therapy group; and 2/ mobile tracked internet devices (e.g.,IPad). The system will ensure maximum openness and dissemination by using 3D Web technologies.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

21

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Nice, France, 06000
        • CHU de Nice
      • Nice, France, 06000
        • Ehpad Valrose
      • Nice, France, 06000
        • EHPAD Villa Hélios Saint Jean

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria to MILD COGNITIVE IMPAIRMENT:

  • Male or Female aged ≥ 60 years.
  • Subject presenting a diagnosis of MCI according to the criteria of the National Institute on Aging and Alzheimer Association group (Albert M.S., 2011) ; or Alzheimer disease at the prodromal stage (Dubois B., 2010 )
  • Subject presenting a score of 0 at the " Tremor " and " Rigidity " items from the UPDRS III
  • Patient not presenting a major depression episode according to the DSM IV-R;
  • Be affiliate to the social security system (For French patients only);
  • Case of patients under guardianship after agreement of the guardian (legal entity);
  • Signed and dated a written informed consent obtained from the subject

Exclusion Criteria to MILD COGNITIVE IMPAIRMENT:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Alzheimer disease

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the participants and careers acceptability
Time Frame: 8 weeks
The primary objective is to evaluate the participants and careers acceptability in short and long term use of the VERVE light portable system used for cognitive stimulation of patients with cognitive pathologies.
8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To assess the impact of behavioral disturbances over the use of the VR using the NPI and the Apathy Inventory
Time Frame: at 3, 4 and 8 weeks
To assess the impact of behavioral disturbances over the use of the VR using the NPI and the Apathy Inventory
at 3, 4 and 8 weeks
To describe the parameters those facilitate engagement within the designs of VERVE VR setting using the engagement scale OME
Time Frame: at 1, 2, 3, a weeks
To describe the parameters those facilitate engagement within the designs of VERVE VR setting using the engagement scale OME
at 1, 2, 3, a weeks
To assess the potential acceptability and preventive effectiveness of such setting in home setting using visual analogic scale and EQ-D6
Time Frame: at 3, 4, 8 weeks
To assess the potential acceptability and preventive effectiveness of such setting in home setting using visual analogic scale and EQ-D6
at 3, 4, 8 weeks
To assess cognitive impact of the light VERVE setting. Using Stroop, TMT, VAT and functional task (IADL)
Time Frame: First day and 4 weeks
To assess cognitive impact of the light VERVE setting. Using Stroop, TMT, VAT and functional task (IADL)
First day and 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Philippe ROBERT, PU-PH, Centre Hospitalier Universitaire de Nice
  • Study Chair: Renaud DAVID, PH, CHU Nice
  • Study Chair: Guillaume SACCO, PH, Centre Hospitalier Universitaire de Nice
  • Study Chair: Jean Michel TURPIN, PH, Centre Hospitalier Universitaire de Nice

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2013

Primary Completion (Actual)

September 1, 2014

Study Completion (Actual)

September 1, 2014

Study Registration Dates

First Submitted

November 21, 2012

First Submitted That Met QC Criteria

February 22, 2013

First Posted (Estimate)

February 25, 2013

Study Record Updates

Last Update Posted (Estimate)

September 1, 2015

Last Update Submitted That Met QC Criteria

August 31, 2015

Last Verified

August 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer's Disease

Clinical Trials on The training by Verve System

3
Subscribe